Skip to main content

Epidemiology and Public Health

The broad purpose of the Epidemiology and Public Health research group is contributing to increase the available scientific evidence regarding preventive interventions, to promote health, and prevent morbidity and mortality from major diseases. Our group uses epidemiological methods to study etiology, surveillance, and efficacy of these interventions. We are primarily focused on epidemiology and prevention of infectious diseases, in both individual and population levels.
Main lines of research:

  • Vaccines: This research line includes the organization, participation and collaboration in different clinical trials related to the evaluation of the immunogenicity, efficacy and safety of different vaccines (e.g. Herpes Zoster, Respiratory Syncytial Virus, Influenza, Covid-19).
  • The epidemiology and prevention of healthcare acquired infections: This research line includes the evaluation of risk factors, characteristics, evolution, host, and impact of these infections. 
  • Clinical Epidemiology of Multiple Sclerosis: The objective of this project is to characterize the epidemiology of Multiple Sclerosis in Catalonia. 

Team

Cristian Quintana Alonso

Cristian Quintana Alonso

Epidemiology and Public Health
Read more
Eva del Amo Moran

Eva del Amo Moran

Research technician
Epidemiology and Public Health
Read more
Irene  Torrecilla Martinez

Irene Torrecilla Martinez

Epidemiology and Public Health
Read more
Jose Angel Rodrigo Pendás

Jose Angel Rodrigo Pendás

Epidemiology and Public Health
Read more
José María Sánchez García

José María Sánchez García

Epidemiology and Public Health
Read more
Laia Pinos  Tella

Laia Pinos Tella

Epidemiology and Public Health
Read more
Cristian Quintana Alonso

Cristian Quintana Alonso

Epidemiology and Public Health
Read more
Eva del Amo Moran

Eva del Amo Moran

Research technician
Epidemiology and Public Health
Read more
Irene  Torrecilla Martinez

Irene Torrecilla Martinez

Epidemiology and Public Health
Read more
Jose Angel Rodrigo Pendás

Jose Angel Rodrigo Pendás

Epidemiology and Public Health
Read more
José María Sánchez García

José María Sánchez García

Epidemiology and Public Health
Read more
Laia Pinos  Tella

Laia Pinos Tella

Epidemiology and Public Health
Read more

Publications

Increase in Incidence Rates and Risk Factors for Multidrug Resistant Bacteria in Septic Children: A Nationwide Spanish Cohort Study (2013-2019).

PMID: 37998828
Journal: Antibiotics-Basel
Year: 2023
Reference: Antibiotics (Basel). 2023 Nov 14;12(11):1626. doi: 10.3390/antibiotics12111626.
Impact factor:
Publication type: Paper in international publication
Authors: Albasha, Hasan; Andreassi, Maria Grazia; Belda-Hofheinz, Sylvia; Bianco, Lisa; Bissell, Malenka M; Body, Simon C; Bustinza-Arriortua, Amaya; Caffarelli, Anthony; Carlisle, Steven G; Citro, Rodolfo et al.
DOI: 10.3390/antibiotics12111626

Safe and optimized use of gadolinium-based contrast agents in neuroimaging.

PMID: 38001249
Journal: EUROPEAN RADIOLOGY
Year: 2023
Reference: Eur Radiol. 2023 Nov 25. doi: 10.1007/s00330-023-10456-y.
Impact factor:
Publication type: Editorail in international publication
Authors: Belda-Hofheinz, Sylvia; Bustinza-Arriortua, Amaya; de Carlos-Vicente, Juan Carlos; Fresan-Ruiz, Elena; Garcia-Soler, Patricia; Herrera-Castillo, Laura Ximena; Jordan-Garcia, Iolanda; Lopez-Herce-Cid, Jesus; Morteruel-Arizcuren, Elvira; Nieto-Moro, Montserrat et al.
DOI: 10.1007/s00330-023-10456-y

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.

PMID: 35795713
Journal: EClinicalMedicine
Year: 2022
Reference: EClinicalMedicine. 2022 Jul 1;50:101529. doi: 10.1016/j.eclinm.2022.101529. eCollection 2022 Aug.
Impact factor: 0
Publication type: Paper in international publication
Authors: Castano, Luis; Borobia, Alberto M; Castillo de la Osa, Maria; Gonzalez-Perez, Maria; Garcia-Perez, Javier; Bertran, Maria Jesus; Campins, Magdalena; Lora, David; Perez-Olmeda, Mayte; Alcami, Jose et al.
DOI: 10.1016/j.eclinm.2022.101529

Characteristics of 24 SARS-CoV-2-Sequenced Reinfection Cases in a Tertiary Hospital in Spain.

PMID: 35722299
Journal: Frontiers in Microbiology
Year: 2022
Reference: Front Microbiol. 2022 May 26;13:876409. doi: 10.3389/fmicb.2022.876409. eCollection 2022.
Impact factor: 5.64
Publication type: Paper in international publication
Authors: Codina, Maria Gema, Martin, Maria Carmen, Castillo, Carla, Garcia-Comunas, Karen, Vasquez-Mercado, Rodrigo, Martins-Martins, Reginald, Colomer-Castell, Sergi, Pumarola, Tomas, Campins, Magda, Quer, Josep et al.
DOI: 10.3389/fmicb.2022.876409

COVID-19: an opportunity of systematic integration for Chagas disease. Example of a community-based approach within the Bolivian population in Barcelona.

PMID: 35346096
Journal: BMC INFECTIOUS DISEASES
Year: 2022
Reference: BMC Infect Dis. 2022 Mar 28;22(1):298. doi: 10.1186/s12879-022-07305-6.
Impact factor: 3.09
Publication type: Paper in international publication
Authors: Gomez I Prat, Jordi, Essadek, Hakima Ouaarab, Esperalba, Juliana, Serrat, Francesc Zarzuela, Guiu, Isabel Claveria, Goterris, Lidia, Zules-Ona, Ricardo, Choque, Estefa, Pastoret, Conxita, Ponces, Natalia Casamitjana et al.
DOI: 10.1186/s12879-022-07305-6

Management of Hospitalized Respiratory Syncytial Virus Bronchiolitis in the Pediatric Ward in Spain: Assessing the Impact of a New Clinical Practice Protocol.

PMID: 34936054
Journal: PEDIATRIC DRUGS
Year: 2022
Reference: Paediatr Drugs. 2022 Jan;24(1):63-71. doi: 10.1007/s40272-021-00488-6. Epub 2021 Dec 22.
Impact factor: 3.022
Publication type: Paper in international publication
Authors: Vila, Jorgina, Lera, Esther, Peremiquel-Trillas, Paula, Martinez, Laia, Barcelo, Irene, Andres, Cristina, Rodrigo-Pendas, Jose Angel, Anton, Andres, Rodrigo, Carlos et al.
DOI: 10.1007/s40272-021-00488-6

Blog

News

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.